Welcome to our dedicated page for Tandem Diabetes news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes stock.
Tandem Diabetes Care (TNDM) delivers innovative insulin management solutions through advanced pump technology and connected diabetes care platforms. This news hub provides investors and healthcare professionals with timely updates on corporate developments, product milestones, and regulatory progress.
Access official press releases covering quarterly financial results, new product clearances, and strategic partnerships alongside analysis of market trends impacting diabetes care technology. Our curated collection ensures you stay informed about pump software updates, clinical trial outcomes, and international expansion efforts.
Key updates include FDA submissions, insulin delivery system enhancements, and operational developments across global markets. Bookmark this page for direct access to Tandem Diabetes' latest announcements, including pump compatibility improvements and user experience initiatives that shape modern diabetes management.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) reported a 13% increase in worldwide GAAP sales to $191.7 million and a 12% increase in non-GAAP sales to $192.8 million for the first quarter of 2024. The company launched Tandem Mobi with Dexcom G6 CGM sensor integration and t:slim X2 with Abbott Freestyle Libre 2 Plus CGM sensor integration in the US, among other initiatives. The increase in pump shipments and financial results showcased positive growth. However, the company reported a net loss for the quarter.
Tandem Diabetes Care, Inc. (TNDM) will present at investor conferences on May 15 and May 29, 2024, providing company updates. The presentations will be webcast live and archived for 30 days.
FAQ
What is the current stock price of Tandem Diabetes (TNDM)?
What is the market cap of Tandem Diabetes (TNDM)?
